Table 2.
Clinical trials of agents targeting VEGF signalling in combination with other targeted agents
| ClinicalTrials.gov identifier | Combination strategy | Stage | Cancer type |
|---|---|---|---|
| NCT01496742 | Bevacizumab plus MET-specific antibody onartuzumab (MetMAb) and standard therapies |
Phase II | Non-small-cell lung cancer |
| NCT01186991 | Bevacizumab plus MET-specific antibody onartuzumab (MetMAb) and paclitaxel |
Phase II | Metastatic triple-negative breast cancer |
| NCT01418222 | Bevacizumab plus MET-specific antibody onartuzumab (MetMAb) and standard therapies |
Phase II | Metastatic colorectal cancer |
| NCT01339039 | Bevacizumab plus CXCR4 inhibitor plerixafor (mozobil and AMD3100) |
Phase I | Recurrent high-grade glioma |
| NCT01251926 | Bevacizumab plus topoisomerase I inhibitor EZN-2208 (pegylated SN-38) |
Phase I | Refractory solid malignancies |
| NCT00811993 | Bevacizumab plus IGF1R inhibitor R1507 and standard therapies | Phase I | Advanced solid malignancies |
| NCT01308684 | Bevacizumab plus PLGF-specific antibody RO5323441 (TB-403) | Phase I | Recurrent high-grade glioma |
| NCT01605227 | Cabozantinib (XL184, inhibitor of VEGFR, MET, AXL and other kinases) versus prednisone (COMET-1 trial) |
Phase III | Castration-resistant prostate cancer metastatic to bone |
| NCT01522443 | Cabozantinib (XL184, inhibitor of VEGFR, MET, AXL and other kinases) versus mitoxantrone and prednisone (COMET-2 trial) |
Phase III | Castration-resistant prostate cancer metastatic to bone |
| NCT00726323 | Foretinib (GSK1363089, XL880, inhibitor of VEGFR, MET and other kinases) |
Phase II | Papillary renal cell carcinoma |
| NCT01468922 | Pazopanib (inhibitor of VEGFRs, PDGFRs and other kinases) and tivantinib (ARQ 197, inhibitor of MET) |
Phase IB | Refractory advanced solid tumours |
CXCR4, chemokine (C-X-C motif) receptor 4; IGF1R, insulin-like growth factor 1 receptor; PDGFR, platelet-derived growth factor receptor; PLGF, placental growth factor; VEGFR, vascular endothelial growth factor receptor.